Cocaine Use Disorder (CUD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Cocaine Use Disorder (CUD) Market Outlook

Thelansis’s “Cocaine Use Disorder (CUD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cocaine Use Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cocaine Use Disorder (CUD) Overview

Cocaine use disorder (CUD) is a significant global public health issue characterized by the compulsive use of cocaine despite its detrimental medical, psychological, and behavioral effects. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), defines CUD as the presence of at least 2 out of 11 criteria causing clinically significant impairment or distress within 12 months. These criteria can be categorized into four groups: physiological (craving, tolerance, and withdrawal), loss of control, prioritization of cocaine over other activities, and negative consequences resulting from cocaine use. The severity of CUD is determined by the number of symptoms present: mild CUD is indicated by two or three symptoms, moderate CUD by four or five symptoms, and severe CUD by six or more symptoms. Continued cocaine use over time carries a high risk of progressing to CUD, particularly among individuals who initiate cocaine use around the age of 20. This younger population often struggles with long-term cessation efforts. Numerous risk factors contribute to the development of CUD, including genetic, environmental, and demographic factors. The hereditary influence on CUD susceptibility is estimated to be up to 65% in women and up to 79% in men. Cocaine's acute effects play a role in driving habitual patterns of use. As a psychostimulant, cocaine stimulates the sympathetic nervous system, resulting in heightened arousal, increased activity, enhanced mood, reduced appetite, and sleep disturbances. Higher doses and faster routes of administration (such as smoking or intravenous injection) can intensify euphoria, thereby increasing the likelihood of addiction development. Individuals with CUD encounter various barriers when seeking treatment; most do not receive the necessary interventions. Currently, no pharmacological treatments are approved by the U.S. Food and Drug Administration (FDA) for CUD.

• The prevalence among 18–25 (5.53%), 26–34 (4.37%), 35–49 (1.70%), and people 50 years or older (0.59%).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: